|
[1]
|
Gomez-Navarro J, Curiel DT, Douglas JT. Gene therapy for cancer[J].Eur J Cancer, 1999, 35(3):867-885. |
|
[2]
|
Weiner DB, Kennedy RC. Genetic vaccines[J]. Sci Am, 1999, 281(1):50-70, |
|
[3]
|
Narimatsu M, Nagayama Y, Akino K, et al. Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line[J]. J Clin Endocrinol Metab, 1998, 83(11):3668-3672. |
|
[4]
|
Blagosklonny MV, Giannakokou P, Wojtowics M, et al. Effects of p53-expression adenovirus on the ehemosensitivity and differentiationofanaplasticthyroidcancercells[J]. JClin Endocrinol Metab,1998, 83(8):2516-2522. |
|
[5]
|
Shimura H, Suzuki H, Miyazaki A, et al. Transcriptional activation of the thyroglobulin promoter directing suicide gene expression by thyroid transcription factor-1 in thyroid cancer cells[J]. Cancer Res, 2001, 61(11):3640-3646. |
|
[6]
|
Kitazono M, Chuman Y, Aikou T, et al. Adenovirus HSV-TK construct with thyroid-specific promoter:Enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the camp pathway[J]. Iht J Cancer, 2002, 99(2):453-459. |
|
[7]
|
Zahng R, De Groot IJ. Gene therapy of established medullary thyroid carcinoma with herpes simplex viral thymidine kinase in a rat tumor model:relationship of bystander effect and antitumor efficacy[J]. Thyroid, 2000, 10(1):313-319. |
|
[8]
|
Zhang R, De Groot IJ. An adenoviral expression functional heterogeneous proteins herpes simplex viral thymidine kinase and human interleukin-2 has enhanced in vivo antitumor activity against medullary thyroid carcinoma[J]. Endocrinol Relat Cancer, 2001, 8(2):315-325. |
|
[9]
|
Yamazaki M, Zhang R, Straus FH, et al. Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor specific expression of intedeukin-12[J]. Gene Therapy,2002, 9(1):64-74. |
|
[10]
|
Soler MN, Bobe P, Benihoud K, et al. Gene therapy of rat medullary thyroid cancer by naked nitric o. xide synthase Ⅱ DNA injection[J]. J Gene Med, 2000, 2(2):344-352. |
|
[11]
|
Zhang R, De Groot LJ. Genetic immunotherapy of established tumors with adenoviral vectors transducing murine interleukin(mIL-12) subunits in a rat medullary thyroid carcinoma model[J]. Clin Endocrinol(Oxf), 2000, 52(3):687-694. |
|
[12]
|
Zhang R, Straus FH, De Groot LJ. Effective genetic therapy of established medullary thyroid carcinomas with murine interleukin2:dissemination and cytotoxicity studies in a rat tumor model[J].Endocrinology, 1999, 140(7):2152-2158. |
|
[13]
|
Filletti S, Bidart JM, Arturi R, et al. Sodium/Iodide symporter:a key transport system in thyroid cancer cell metabolism[J]. Eur J Endocrinol, 1999, 141(2):443-457. |
|
[14]
|
Venkataraman GM, Yatin M, Mareinek R, et al. Restoration of iodine uptake in dedifferentiated thyroid carcinoma relationship to human Na+/I- symporter gene methylation status[J]. J Clin Endocrinol and Metab, 1999, 84(8):2449-2460. |
|
[15]
|
Haupt K, Siegel F, Lu M, et al. Induction of a cellular and humoral immune response against the tumor associated antigen calcitolin by geneticimmunization[J]. J Endocrinol Investig, 1999, 22(supple):4. |
|
[16]
|
Juweid ME, Hajjar G, Swayne LC, et al. Phase Ⅰ/Ⅱ trial of 131I-MN14F (ab)2 anticarcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma[J].Cancer, 1999, 85(6):1828-1842. |
|
[17]
|
Simon D, Kohrle J, Reiners C, et al. Redifferentiation therapy with retinoids-a therapeutic option in advanced follicular and papillary thyroid carcinoma[J]. World J Surg, 1998, 22(2):569-574. |
|
[18]
|
Simon D, Kohrle J, Reiners C, et al. Redifferentiation therapy in thyroid cancer-results of a multicenter pilot study[J]. Thyroid, 1998,8(4):1217. |
|
[19]
|
Schmutaler C, Koehrle J. Innovative strategies for the treatment of thyroid cancer[J]. Eur J Endocrinol, 2000, 143(1):15-24. |
|
[20]
|
Signore A, Annovazzi A, Chianelli M, et al. Peptide radio-pharmaceuticals for diagnosis and therapy[J]. Eur J Nucl Med, 2001, 28(5):1555-1556. |
|
[21]
|
Oberg K. Established clinical use of octreotide and lanreotide in oncology[J]. Chemotherapy, 2001, 47(1):47-63. |
|
[22]
|
Weiner RE, Thakur ML. Radilabaled peptides in the diagnosis and therapy of oncological disease[J]. Appl Radiat Isot, 2002, 57(2):749-763. |
|
[23]
|
Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging[J].Semin Nucl Med, 2002, 32(1):84-91. |
|
[24]
|
Lamberts SWL, de Herder WW, Hofland LJ. Somatostatin analogs in the diagnosis and treatment of cancer[J]. Trends Endocrinol Metab,2002, 13(2):451-502. |
|
[25]
|
Papotti M, Kumar U,Volante M, et al. Immunohistochemical detection of somatostatin types 1-5 in medullary carcinoma of the thyroid[J]. Clin Endocrinol, 2001, 54(2):641-649. |
|
[26]
|
Slooter GD, Mearadji A,Breeman WAP, et al. Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumors[J]. Br J Surg, 2003, 88(1):31-40. |
|
[27]
|
Boerman OC, Oyen WJG, Corstens FHM. Radio-labeled receptor binding peptides:a new class of radiopharmaceutical[J]. Semin Nucl Med, 2001, 30(1):195-208. |
|
[28]
|
Kwekkeboom DJ, Krenning EP, de Jong M. Peptide receptor imaging and therapy[J]. J Nucl Med, 2002, 41(6):1704-1713. |
|
[29]
|
Bugal JE, Erion JL, Johnson MA, et al. Radiothapeutical efficacy of 153-Sm-CMDTPA-Tyr3-octreotide in tumor-bearing rats[J]. Nucl Med Biol, 2001, 28(1):327-334. |
|
[30]
|
Bohuslavizki KH. Somatostatin receptor imaging:current status and future perspectives[J]. J Nucl Med, 2003, 42(3):1057-1058. |
点击查看大图
下载: